Search research articles
Contact Us
Filters
Showing results (151-160 of 181) with videos related to
Page
of 19
Sort By:
The Oncologist
|
June 16, 2021
A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors
Hui K Gan, Michael Millward, Mathilde Jalving, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2021
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
E Gabriela Chiorean, Katherine A Guthrie, Philip A Philip, et al.
Journal for Immunotherapy of Cancer
|
November 29, 2023
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors
Todd M Bauer, Armando Santoro, Chia-Chi Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 24, 2018
Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update
Davendra P S Sohal, Erin B Kennedy, Alok Khorana, et al.
Cancer Research Communications
|
March 27, 2023
A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas
Manuel Hidalgo, Rocio Garcia-Carbonero, Kian-Huat Lim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 7, 2020
Metastatic Pancreatic Cancer: ASCO Guideline Update
Davendra P S Sohal, Erin B Kennedy, Pelin Cinar, et al.
Oncotarget
|
September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
Haeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
The New England Journal of Medicine
|
May 6, 2026
Daraxonrasib in Previously Treated Advanced <i>RAS</i>-Mutated Pancreatic Cancer
Brian M Wolpin, Wungki Park, Ignacio Garrido-Laguna, et al.
JCO Clinical Cancer Informatics
|
March 13, 2023
Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma
Matthew A Firpo, Kenneth M Boucher, Josh Bleicher, et al.
The New England Journal of Medicine
|
June 1, 2026
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
Eileen M O'Reilly, Zev A Wainberg, Andrew E Hendifar, et al.
Page
of 19
Search research articles
Search
Showing results (151-160 of 181) with videos related to
Sort By:
Page
of 19
The Oncologist
|
June 16, 2021
A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors
Hui K Gan, Michael Millward, Mathilde Jalving, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2021
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
E Gabriela Chiorean, Katherine A Guthrie, Philip A Philip, et al.
Journal for Immunotherapy of Cancer
|
November 29, 2023
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors
Todd M Bauer, Armando Santoro, Chia-Chi Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 24, 2018
Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update
Davendra P S Sohal, Erin B Kennedy, Alok Khorana, et al.
Cancer Research Communications
|
March 27, 2023
A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas
Manuel Hidalgo, Rocio Garcia-Carbonero, Kian-Huat Lim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 7, 2020
Metastatic Pancreatic Cancer: ASCO Guideline Update
Davendra P S Sohal, Erin B Kennedy, Pelin Cinar, et al.
Oncotarget
|
September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
Haeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
The New England Journal of Medicine
|
May 6, 2026
Daraxonrasib in Previously Treated Advanced <i>RAS</i>-Mutated Pancreatic Cancer
Brian M Wolpin, Wungki Park, Ignacio Garrido-Laguna, et al.
JCO Clinical Cancer Informatics
|
March 13, 2023
Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma
Matthew A Firpo, Kenneth M Boucher, Josh Bleicher, et al.
The New England Journal of Medicine
|
June 1, 2026
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
Eileen M O'Reilly, Zev A Wainberg, Andrew E Hendifar, et al.
Page
of 19